drugset / Trial / NCT03960450

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Topical Administration of BOS-475 in Healthy Subjects and Patients With Psoriasis

NCT03960450

Phase 1 Completed 20 enrolled Boston Pharmaceuticals
RandomizedSequentialTriple-blindTreatment

Summary

This study was conducted to evaluate the safety and tolerability of BOS-475 following single and repeat topical administration to healthy participants (Part A), and to evaluate the safety and tolerability of 42-day repeat topical administration of BOS-475 to participants with plaque psoriasis (Part B).

Timeline

Start
2019-04-23
Primary completion
2020-01-28
Completion
2020-01-28

Drugs

EvaluationDrugModalityDoseRoute
Subject BOS-475 Unknown 0.5 % Topical
Subject BOS-475 Unknown 1 % Topical
Subject BOS-475 Unknown 2 % Topical

Indications